Abstract:Objective: To evaluate the diagnostic value of metagenomic sequencing technology based on Illumina and Nanopore sequencing platforms for patients with suspected lower respiratory tract infection whose pathogen could not be identified by conventional microbiological tests. Methods: Patients admitted to the Respiratory and Critical Care Medicine in Shanghai Ruijin Hospital were retrospectively studied from August 2021 to March 2022. Alveolar lavage or sputum was retained in patients with clinically suspected lower respiratory tract infection who were negative in conventional tests. Bronchoalveolar lavage fluid (BALF) samples were obtained using bronchoscopy. Sputum samples were collected, while BALF samples were not available due to bronchoscopy contraindications. Samples collected from enrolled patients were simultaneously sent for metagenomic sequencing on both platforms. Results: Thirty-eight patients with suspected LRTI were enrolled in this study, consisting of 36 parts of alveolar lavage and 2 parts of sputum. According to the infection diagnosis, 31 patients were confirmed to be infected with pathogens, while 7 patients were diagnosed with non-infectious disease. With regard to the diagnosis of infectious diseases, the sensitivity and specificity of Illumina and Nanopore to diagnose infection in patients were 80.6% vs . 93.5% and 42.9 vs . 28.6%, respectively. In patients diagnosed with bacterial, Mycobacterium , and fungal infections, the positive rates of Illumina and Nanopore sequencer were 71.4% vs . 78.6%, 36.4% vs . 90.9%, and 50% vs . 62.5%, respectively. In terms of pathogen diagnosis, the sensitivity and specificity of pathogens detected by Illumina and Nanopore were 55.6% vs . 77.8% and 42.9% vs . 28.6%, respectively. Among the patients treated with antibiotics in the last 2 weeks, 61.1% (11/18) and 77.8% (14/18) cases of pathogens were accurately detected by Illumina and Nanopore, respectively, among which 8 cases were detected jointly. The consistency between Illumina and diagnosis was 63.9% (23/36), while the consistency between Nanopore and diagnosis was 83.3% (30/36). Between Illumina and Nanopore sequencing methods, the consistency ratio was 55% (22/42) based on pathogen diagnosis. Conclusion: Both platforms play a certain value in infection diagnosis and pathogen diagnosis of CMT-negative suspected LRTI patients, providing a theoretical basis for clinical accurate diagnosis and symptomatic treatment. The Nanopore platform demonstrated potential advantages in the identification of Mycobacterium and could further provide another powerful approach for patients with suspected Mycobacterium infection.

Diagnosis and treatment of refractory infectious diseases using nanopore sequencing technology: Three case reports

Rapid Detection of Potential New Pathogens in Patient Using High -Throughput Sequencing

Nanopore sequencing of infectious fluid is a promising supplement for gold-standard culture in real-world clinical scenario

The Application of Nanopore Targeted Sequencing for Pathogen Diagnosis in Bronchoalveolar Lavage Fluid of Patients with Pneumonia: a Prospective Multicenter Study.

The application of nanopore targeted sequencing in the diagnosis and antimicrobial treatment guidance of bloodstream infection of febrile neutropenia patients with hematologic disease

Application of Nanopore Sequencing in the Diagnosis and Treatment of Pulmonary Infections

Metagenomic identification of pathogens and antimicrobial-resistant genes in bacterial positive blood cultures by nanopore sequencing

A Dual-Process of Targeted and Unbiased Nanopore Sequencing Enables Accurate and Rapid Diagnosis of Lower Respiratory Infections

Same Day Simultaneous Diagnosis of Bacterial and Fungal Infections in Clinical Practice by Nanopore Targeted Sequencing

Nanopore Sequencing Technology: A Reliable Method for Pathogen Diagnosis in Elderly Patients with Community-Acquired Pneumonia

The application of targeted nanopore sequencing for the identification of pathogens and resistance genes in lower respiratory tract infections

A rapid bacterial pathogen and antimicrobial resistance diagnosis workflow using Oxford nanopore adaptive sequencing method

Prospective evaluation of nanopore-based metagenomic sequencing for rapid detection of bacterial pathogens in patients with lower respiratory tract infections

Improved Targeting of the 16S Rdna Nanopore Sequencing Method Enables Rapid Pathogen Identification in Bacterial Pneumonia in Children.

Application of Nanopore Sequencing in Diagnosis of Secondary Infections in Patients with Severe COVID-19.

Molecular rapid diagnostic testing for bloodstream infections: Nanopore targeted sequencing with pathogen-specific primers

The Applications of Nanopore Sequencing Technology in Pathogenic Microorganism Detection

Application and Prospect of Nanopore Sequencing Technology in Etiological Diagnosis of Blood Stream Infection

Illumina and Nanopore sequencing in culture-negative samples from suspected lower respiratory tract infection patients

The clinical utility of Nanopore 16S rRNA gene sequencing for direct bacterial identification in normally sterile body fluids

Metagenomic Diagnosis For A Culture-Negative Sample From A Patient With Severe Pneumonia By Nanopore And Next-Generation Sequencing